Scientific basis
Systemic Lupus Erythematosus is a chronic, multi-system autoimmune disease, with increased disease severity in non-European ancestries and more females than males with lupus. The relapsing-remitting disease course makes it challenging to treat successfully.
We have a long-standing interest in two TNF superfamily genes, (OX40 and OX40L), as independent risk factors for SLE, as membrane-bound (mOX40) and serum (sOX40) proteins. The mechanism of production for sOX40 is unknown, but may involve alternative-splicing or cleavage by metalloproteinases (MMP). A co-stimulatory immune signal produced when OX40 binds to its unique receptor, OX40L, is an important regulatory factor for SLE (a disease of increased immune activity). We have both genetic associations and functional data to drive our interest in OX40.
Aims
1) Investigate how genetic variation at OX40 impacts production of sOX40
2) Infer the cellular source of sOX40
3) Ascertain whether levels of sOX40 in human T-cells are correlated with increased expression of specific OX40 transcript isoforms or MMP transcripts
4) Establish whether increased sOX40 is correlated with specific OX40 transcript isoforms or whether production of sOX40 is prevented by MMP-blocking agents in cultured T-cells.
Techniques and skills
Multi-omic analysis of GWAS and scRNA-Seq datasets; multi-analyte immunoassay (MSD), multi-parameter flow cytometry (Cytek Aurora), cell culture, bioinformatics
Objectives for each year
Year 1: Measure sOX40 by multi-analyte immunoassays, in SLE patients and healthy controls selected on the basis of OX40 genotype. In accompanying scRNA-Seq data discover whether specific OX40 transcript isoforms or MMP transcripts are correlated with high levels of sOX40.
Year 2: Determine the OX40+ cell-type correlated with the highest serum level of OX40 using flow cytometry in SLE T-cells and healthy controls.
Year 3: Establish whether activation of Jurkat T-cells changes the proportion of OX40 transcript isoforms or whether production of OX40 is reduced using MMP-blocking agents.